A Phase 4 interventional study of Benzoyl Peroxide and Dermotivin® Soft Liquid cleanser in Acne Vulgaris, sponsored by Galderma R&D. Completed at 1 site in Germany. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2021-02-18.
Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 4, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing Benzoyl Peroxide in Acne Vulgaris — none open to participants now, 1 under way, none of them phase 3. Benzoyl Peroxide · Acne Vulgaris.
Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, this one is the 24th largest by enrollment, is one of 5 that started in 2015, is one of 16 in phase 4, and was the 27th registered.
791 studies on the registry are indexed under Acne Vulgaris; 93 are open to participants now.
Browse Acne Vulgaris studies →None of the 33 studies testing Benzoyl Peroxide in Acne Vulgaris is open now. The open studies under Acne Vulgaris, anywhere →
Benzoyl Peroxide: first FDA approval 1984 (BENZAMYCIN). What it is approved for, and how studies give it, is on its page →
Of the 46 Acne Vulgaris studies recruiting now, 16 (35%) set no upper age limit and 29 (63%) stop at 75 or younger; 21 take children under 18; 17 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 70 across 673 interventional studies indexed under Acne Vulgaris.
Median enrollment 90 across the 33 interventional studies. Of the 28 that completed or were terminated, 24 (86%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 33 have an industry lead sponsor. The 10 most frequent:
This study is registered under Galderma R&D, one of the names counted as Galderma Group AG. Under that name alone:
Galderma R&D is the lead sponsor of 284 studies on the registry; 11 are open to participants now.
Of its 60 completed or terminated interventional studies of FDA-regulated products, 55 (92%) have results posted.
49 studies in Acne Vulgaris by Galderma Group AG: none open now, 1 under way, 1 of them phase 3. Of 48 finished, 39 (81%) have results posted.
Among the 49 studies in Acne Vulgaris by Galderma Group AG, this one is the 39th largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2015, is one of 20 in phase 4, and was the 39th registered.
Galderma Group AG’s Acne Vulgaris studies by the year they started, since 2004.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing Benzoyl Peroxide in Acne Vulgaris, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Galderma Group AG’s 49 in Acne Vulgaris:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of this study is to evaluate a complete acne regimen consisting of a medication (Benzaknen® 5% Gel), and 2 cosmetic products Dermotivin® Soft Liquid soap and Cetaphil® Dermacontrol Moisturizer SPF30 in patients with acne.
The main objective of this study is to evaluate subject satisfaction with the treatment regimen comprising Benzaknen® 5% Gel in association with 2 cosmetic products including a foam soap, Dermotivin® Soft Liquid soap, and a non comedogenic moisturizer, Cetaphil® Dermacontrol Moisturizer SPF30, in patients with mild to moderate acne, after 12 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Benzac® 5% Gel (once daily) + Dermotivin® Soft Liquid soap (twice daily) + Cetaphil® Dermacontrol Moisturizer SPF30 (once daily)
Drug: Benzoyl Peroxide · Other: Dermotivin® Soft Liquid cleanser · Other: Cetaphil® Dermacontrol Moisturizer SPF30
Number of Participants Satisfied and Very Satisfied With Regimen
Number of subjects satisfied and very satisfied with the three-part treatment regimen
Time frame: 12 weeks
| Milestone | Three-part Treatment Regimen |
|---|---|
| Started | 50 |
| Completed | 46 |
| Not completed | 4 |
| Withdrew: Adverse event | 3 |
| Withdrew: Withdrawal by subject | 1 |
Number of subjects satisfied and very satisfied with the three-part treatment regimen
| participants | Treatment Regimen |
|---|---|
| Number of Participants Satisfied and Very Satisfied With Regimen | 42 |
Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Three-part Treatment Regimen | 0/50 (0%) | 1/50 (2%) | 13/50 (26%) |
| Event | Three-part Treatment Regimen |
|---|---|
| HypersensitivityImmune system disorders | 1/50 |
| Dyspnoea exertionalRespiratory, thoracic and mediastinal disorders | 1/50 |
| Event | Three-part Treatment Regimen |
|---|---|
| NasopharyngitisInfections and infestations | 4/50 |
| Skin irritationSkin and subcutaneous tissue disorders | 3/50 |
| LacerationInjury, poisoning and procedural complications | 1/50 |
| Radius fractureInjury, poisoning and procedural complications | 1/50 |
| BlepharitisImmune system disorders | 1/50 |
| DiarrhoeaGastrointestinal disorders | 1/50 |
| AcneSkin and subcutaneous tissue disorders | 1/50 |
| RashSkin and subcutaneous tissue disorders | 1/50 |
| Skin exfoliationSkin and subcutaneous tissue disorders | 1/50 |
| TenosynovitisMusculoskeletal and connective tissue disorders | 1/50 |
Intent-to-Treat population
| Age, Categorical(Participants) | Three-part Treatment Regimen |
|---|---|
| <=18 years | 21 |
| Between 18 and 65 years | 29 |
| >=65 years | 0 |
| Age, Continuous(years) | Three-part Treatment Regimen |
|---|---|
| Mean | 21.8 ± 8 |
| Sex: Female, Male(Participants) | Three-part Treatment Regimen |
|---|---|
| Female | 33 |
| Male | 17 |
| Race and Ethnicity Not Collected(Participants) | Three-part Treatment Regimen |
|---|
| Region of Enrollment(Participants) | Three-part Treatment Regimen |
|---|---|
| Germany | 50 |
| Skin phototype(Participants) | Three-part Treatment Regimen |
|---|---|
| Phototype I | 1 |
| Phototype II | 25 |
| Phototype III | 21 |
| Phototype IV | 3 |
| Investigator Global Assessment(Participants) | Three-part Treatment Regimen |
|---|---|
| Mild | 37 |
| Moderate | 13 |
| Severe | 0 |
| Acne duration(Years) | Three-part Treatment Regimen |
|---|---|
| Mean | 9.8 ± 7.4 |
3 further baseline measures are reported on the registry.
The record gives a start of Aug 2015, a primary completion of Jan 2016 and a completion of Jan 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2019, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Benzoyl Peroxide